Praxis Precision Medicines (PRAX) Projected to Post Earnings on Monday

Praxis Precision Medicines (NASDAQ:PRAX) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($3.20) per share and revenue of $0.18 million for the quarter.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

NASDAQ PRAX opened at $38.35 on Friday. Praxis Precision Medicines has a 1 year low of $26.70 and a 1 year high of $91.83. The business’s fifty day moving average is $35.62 and its two-hundred day moving average is $60.92. The stock has a market capitalization of $781.15 million, a P/E ratio of -3.72 and a beta of 2.65.

Analyst Ratings Changes

PRAX has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $80.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, May 5th. Wedbush increased their price target on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an “underperform” rating in a research report on Monday, May 5th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Praxis Precision Medicines in a research note on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price objective on the stock. Robert W. Baird decreased their target price on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $105.00 price target on shares of Praxis Precision Medicines in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $116.50.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.